Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund
～Targeting treatments for infectious diseases that burden the developing countries～

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President and CEO: Masayuki Mitsuka) has endorsed the objectives of the Global Health Innovative Technology Fund (GHIT Fund) and has decided to participate in a screening program together with the Drugs for Neglected Diseases initiative (DNDi), which is a new drug development initiative. DNDi is conducting R&D in new treatment agents and treatment methods, centered on tropical infectious diseases. In addition, research funding for this program (approximately ¥15 million) will be received from the GHIT Fund.

The Company has concluded a joint agreement for this program with the GHIT Fund and DNDi, and the Company’s compound library (50,000 compounds) will be provided to DNDi through the framework of the GHIT Fund screening program. The parties will then commence joint screening, targeting the discovery of new drug candidates for Chagas disease and leishmaniasis.

In accordance with the corporate philosophy of “contributing to the healthier lives of people around the world through the creation of pharmaceuticals,” Mitsubishi Tanabe Pharma has identified “Social contribution activities for health” as one of the important material issues that it needs to address. The Company has positioned the series of initiatives coordinated through the GHIT Fund as important endeavors in regard to materiality, and believes that these initiatives will directly contribute to the improvement of access to medicines in developing countries and to the realization of the SDGs.

Moving forward, Mitsubishi Tanabe Pharma will work to contribute to the realization of a sustainable society by making a contribution to the health of people around the world through the discovery of drugs that address unmet medical needs and through participation in the GHIT Fund and other initiatives.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110